Masayoshi Son, SoftBank CEO (glen photo/Shutterstock)
February 10, 2021 07:31 AM EST
Financing

A year af­ter FTC nixed Il­lu­mi­na buy­out, Soft­Bank bets $900M on PacBio's new vi­sion

Jason Mast

Editor

A year af­ter the FTC killed Pa­cif­ic Bio­sciences’ $1.2 bil­lion buy­out by Il­lu­mi­na, Cal­i­for­nia’s small­er ge­nom­ic se­quenc­ing com­pa­ny has found a far dif­fer­ent group …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

Met­sera rais­es $215M for stud­ies of GLP-1 and amylin obe­si­ty drugs

Adap­ti­m­mune's sec­ond T cell re­cep­tor cell ther­a­py for rare sar­co­mas pass­es piv­otal test

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

J&J takes 340B fight with fed­er­al gov­ern­ment to court

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times